Lung Cancers Today
Advertisement
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Sunvozertinib is an irreversible EGFR inhibitor that targets a wide spectrum of EGFR mutations.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
For patients with NSCLC and EGFR mutations, amivantamab plus carboplatin-pemetrexed shows OS benefits versus chemo alone.
The improvement in median OS with the combination treatment is “expected to exceed one year," officials said.
The study showed there was “preliminary evidence of central nervous system-anti-tumor activity” in some patients.
The TROPiCS-03 trial, a multicohort, open-label basket study, is assessing the antibody-drug conjugate in solid tumors.
The therapy is now the “first and only subcutaneously administered PD-1 inhibitor," officials said in an announcement.
Lauren Averett Byers, MD, will be honored with the award during the TAMEST Annual Conference in February.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Home-based exercise programs after lung cancer resection do not improve physical function in patients with NSCLC.
Study Highlights Importance of Pretreatment Frailty Assessments for Older Adults With Advanced NSCLC
Implementing pretreatment frailty assessments into clinical workflows may help identify patients at risk of poor outcomes.
A new study illustrated the importance of exercise for patients with lung cancer who experience cancer-related fatigue.
Researchers evaluated if commercially available AI software was capable of detecting lung cancer in chest radiographs.
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
This follows the FDA’s August 2024 move to grant Priority Review for the subcutaneous amivantamab BLA.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Researchers say the conventional criteria may underestimate the condition in Asian patients with lung cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.